Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.

Liu X, Zhang H, Lai L, Wang X, Loera S, Xue L, He H, Zhang K, Hu S, Huang Y, Nelson RA, Zhou B, Zhou L, Chu P, Zhang S, Zheng S, Yen Y.

Clin Sci (Lond). 2013 May;124(9):567-78. doi: 10.1042/CS20120240.


Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.

Han P, Lin ZR, Xu LH, Zhong Q, Zhu XF, Liang FY, Cai Q, Huang XM, Zeng MS.

Mol Med Rep. 2015 Jul;12(1):401-9. doi: 10.3892/mmr.2015.3360. Epub 2015 Feb 16.


The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.

Huang Y, Liu X, Wang YH, Yeh SD, Chen CL, Nelson RA, Chu P, Wilson T, Yen Y.

Urol Oncol. 2014 Jan;32(1):51.e9-19. doi: 10.1016/j.urolonc.2013.08.002.


Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.

Xie H, Lin J, Thomas DG, Jiang W, Liu X.

Int J Clin Exp Pathol. 2012;5(4):347-55. Epub 2012 Apr 16.


Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.

Zhang H, Liu X, Warden CD, Huang Y, Loera S, Xue L, Zhang S, Chu P, Zheng S, Yen Y.

BMC Cancer. 2014 Sep 11;14:664. doi: 10.1186/1471-2407-14-664.


Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.

Lu AG, Feng H, Wang PX, Han DP, Chen XH, Zheng MH.

World J Gastroenterol. 2012 Sep 14;18(34):4704-13.


E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.

Fang Z, Gong C, Liu H, Zhang X, Mei L, Song M, Qiu L, Luo S, Zhu Z, Zhang R, Gu H, Chen X.

Biochem Biophys Res Commun. 2015 Aug 21;464(2):407-15. doi: 10.1016/j.bbrc.2015.06.103. Epub 2015 Jun 18.


Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Fisher SB, Fisher KE, Patel SH, Lim MG, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Farris AB 3rd, Maithel SK.

Cancer. 2013 Jan 15;119(2):454-62. doi: 10.1002/cncr.27739. Epub 2012 Jul 3.


KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.

Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A, Shirasawa S.

Anticancer Res. 2011 Jul;31(7):2535-9.


Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers.

Wang X, Liu X, Li AY, Chen L, Lai L, Lin HH, Hu S, Yao L, Peng J, Loera S, Xue L, Zhou B, Zhou L, Zheng S, Chu P, Zhang S, Ann DK, Yen Y.

Clin Cancer Res. 2011 Apr 15;17(8):2570-80. doi: 10.1158/1078-0432.CCR-10-2542. Epub 2011 Jan 20.


High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.

Lee B, Ha SY, Song DH, Lee HW, Cho SY, Park CK.

Gut Liver. 2014 Nov;8(6):662-8. doi: 10.5009/gnl13392. Epub 2014 Nov 15.


Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer.

Wang Q, Liu X, Zhou J, Huang Y, Zhang S, Shen J, Loera S, Yuan X, Chen W, Jin M, Shibata S, Liu Y, Chu P, Wang L, Yen Y.

PLoS One. 2013 Jul 29;8(7):e70191. doi: 10.1371/journal.pone.0070191. Print 2013.


Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.

Zhang M, Wang J, Yao R, Wang L.

Int J Gynecol Cancer. 2013 May;23(4):659-66. doi: 10.1097/IGC.0b013e318287e2b3.


Overexpression of catalytic subunit M2 in patients with ovarian cancer.

Wang LM, Lu FF, Zhang SY, Yao RY, Xing XM, Wei ZM.

Chin Med J (Engl). 2012 Jun;125(12):2151-6.


Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.

Kang W, Tong JH, Chan AW, Zhao J, Wang S, Dong Y, Sin FM, Yeung S, Cheng AS, Yu J, To K.

Oncol Rep. 2014 Jun;31(6):2579-86. doi: 10.3892/or.2014.3148. Epub 2014 Apr 23.


Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.

Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T, Fukayama M.

Hum Pathol. 2010 Dec;41(12):1742-8. doi: 10.1016/j.humpath.2010.06.001. Epub 2010 Sep 9.


RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.

Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE.

Oncogene. 2004 Feb 26;23(8):1539-48.


Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.

Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME.

Clin Cancer Res. 2007 Apr 1;13(7):2207-15.


Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.

Putluri N, Maity S, Kommagani R, Creighton CJ, Putluri V, Chen F, Nanda S, Bhowmik SK, Terunuma A, Dorsey T, Nardone A, Fu X, Shaw C, Sarkar TR, Schiff R, Lydon JP, O'Malley BW, Ambs S, Das GM, Michailidis G, Sreekumar A.

Neoplasia. 2014 May;16(5):390-402. doi: 10.1016/j.neo.2014.05.007. Erratum in: Neoplasia. 2014 Aug;16(8):678. Kommangani, Ramakrishna [corrected to Kommagani, Ramakrishna].

Supplemental Content

Support Center